Not on my reading on their announcement
The bigger question is why did they need to transfer to a GMP facility to make these new doses?
Answer, because someone's regulations ( US Dept of defence for example, Indonesian trial requirement, expanded diabetic foot ulcer trials) require the product to be made to full GMP requirements.
Which means they are producing doses in higher amounts to fulfill expectations of requirements for one or more of these trials.
So it is a step in the right direction and a sign of momentum, that has been lacking until recently.
Not on my reading on their announcementThe bigger question is...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
30.5¢ |
Change
-0.010(3.17%) |
Mkt cap ! $87.95M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 31.0¢ | 30.0¢ | $25.09K | 82.18K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 32855 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 16280 | 1 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |